Creative Planning Boosts Stock Holdings in Haleon PLC Sponsored ADR $HLN

Creative Planning lifted its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 16.4% in the second quarter, HoldingsChannel.com reports. The fund owned 454,621 shares of the company’s stock after purchasing an additional 64,021 shares during the period. Creative Planning’s holdings in Haleon were worth $4,714,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. Hanson & Doremus Investment Management lifted its position in Haleon by 234.1% during the second quarter. Hanson & Doremus Investment Management now owns 2,372 shares of the company’s stock valued at $25,000 after purchasing an additional 1,662 shares in the last quarter. Banque Transatlantique SA purchased a new position in shares of Haleon in the first quarter worth $27,000. Golden State Wealth Management LLC boosted its stake in Haleon by 107.6% during the second quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock valued at $28,000 after buying an additional 1,410 shares during the last quarter. Ransom Advisory Ltd bought a new position in shares of Haleon during the 1st quarter valued at approximately $31,000. Finally, Deutsche Bank AG grew its stake in shares of Haleon by 267.8% in the 1st quarter. Deutsche Bank AG now owns 3,126 shares of the company’s stock worth $32,000 after buying an additional 2,276 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on HLN. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Price Performance

Shares of NYSE HLN opened at $9.86 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The stock has a market capitalization of $43.91 billion, a price-to-earnings ratio of 25.28, a PEG ratio of 2.95 and a beta of 0.20. The firm’s 50 day simple moving average is $9.26 and its 200-day simple moving average is $9.89. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.